Appeals Court Blocks Nationwide Mailing of Abortion Pills in Landmark Ruling

A federal appeals court on Friday blocked the mailing of the abortion pill mifepristone under current Food and Drug Administration rules, a decision that effectively restricts abortion pill access nationwide and sets the stage for a likely Supreme Court battle.

The 5th U.S. Circuit Court of Appeals ruling requires women to see a medical professional in person to obtain mifepristone, reinstating a requirement that had been lifted during the COVID-19 pandemic under the Biden administration. The court acknowledged its decision would “as a practical matter, have a nationwide effect” even in states where abortion remains legal.

“Every abortion facilitated by FDA’s action cancels Louisiana’s ban,” the court wrote, siding with arguments from pro-life states that federal policy undermined their abortion laws. The ruling added that Louisiana’s policy recognizes “every unborn child is [a] human being… from the moment of conception.”

Mifepristone, one of two drugs commonly used in medication abortions, accounts for a majority of abortions in the United States, according to research from the Guttmacher Institute. The court’s order effectively halts pharmacy-based dispensing allowed under recent FDA rule changes and blocks mail-order distribution of the drug.

In their decision, the judges sharply criticized the FDA’s handling of mifepristone’s safety data, saying the agency had “previously eliminated the requirement to report mifepristone’s adverse events,” and called it “unreasonable” to remove reporting requirements and then cite the resulting lack of data to justify expanded access.

The ruling marks a significant escalation in the legal battle over abortion medications following the Supreme Court’s 2022 decision overturning Roe v. Wade. It pits federal regulators against states seeking to enforce stricter abortion laws.

Pro-life groups quickly celebrated the decision. “This is a win we’ve been waiting for, and we pray it holds,” said Students for Life President Kristan Hawkins. “We can’t remain the United States of America if abortion loving states allow criminal enterprises to be set up, breaking the laws of their pro-life neighbors.”

Family Research Council President Tony Perkins called the ruling “great news for the unborn,” adding that the issue “should be before the U.S. Supreme Court soon.”

Pro-choice advocates expressed strong opposition to the decision. New York Attorney General Letitia James said mifepristone is “safe, effective, and essential,” and called the ruling “yet another cruel attack on abortion access.” She added, “Restrictions on abortion care are restrictions on life-saving health care.”

The court’s decision reverses a temporary ruling from last month by federal Judge David C. Joseph, who had allowed mifepristone to remain available by mail while legal challenges and federal review efforts continued. Joseph had cautioned against “government by lawsuit,” emphasizing that the FDA’s ongoing safety review, not litigation, should determine long-term policy.

That safety review remains underway, with the Department of Health and Human Services and FDA examining safety data, adverse events, and the regulatory framework surrounding mifepristone.

Louisiana Attorney General Liz Murrill had argued that expanded access to abortion medication was designed to “reach into jurisdictions like Louisiana” despite state-level abortion restrictions, and caused “irreparable harm every day” it remained in place.

The ruling creates a complex regulatory landscape for abortion access across the country. Even in states where abortion remains legal, the requirement for in-person dispensing could significantly limit access, particularly for women in rural areas or those facing financial or logistical barriers to healthcare.

Medical organizations have previously asserted that mifepristone has a strong safety record, with complications occurring in less than 1% of cases. However, pro-life groups and some medical professionals have questioned the FDA’s monitoring and reporting requirements.

Friday’s ruling now sets up a likely appeal to the Supreme Court, where justices will face another high-stakes decision on reproductive rights less than two years after overturning Roe v. Wade. The case could become a focal point for debates about federal authority over medication regulation versus states’ rights to regulate abortion within their borders.

The Supreme Court’s eventual decision could have profound implications not only for abortion access but also for the FDA’s broader regulatory authority over medications and the relationship between federal and state jurisdiction in healthcare policy.